Literature DB >> 22981677

Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin.

Naoki Aizawa1, Yukio Homma, Yasuhiko Igawa.   

Abstract

BACKGROUND: Mirabegron is the first β3-adrenoceptor agonist that is clinically effective for overactive bladder.
OBJECTIVE: The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin. DESIGN, SETTING, AND PARTICIPANTS: Female Sprague-Dawley rats were anesthetized. The SAAs generated from left L6 dorsal roots were identified by electrical stimulation of the left pelvic nerve and bladder distension. Nerves with conduction velocities (CVs) >2.5 m/s were designated as Aδ-fibers, and nerves with CVs<2.5 m/s were designated as C-fibers. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Two measurements were performed in separate animals. First, after measuring the baselines of SAA during constant filling cystometry, the procedure was repeated with each intravenous administration of mirabegron at three doses-0.1, 0.3, and 1.0mg/kg-cumulatively. Second, the bladder was filled with saline until the intravesical pressure reached 30 cm H(2)O and was kept under an isovolumetric condition; then the recording was performed for 5 min with vehicle and mirabegron or oxybutynin administrated intravenously. RESULTS AND LIMITATIONS: A total of 74 single-unit afferent fibers were isolated from 55 rats (Aδ-fibers: n=34; C-fibers: n=40). SAAs of both Aδ-fibers and C-fibers in response to bladder filling significantly decreased after mirabegron administration in a dose-dependent manner, which was more remarkable for Aδ-fibers. During an isovolumetric condition of the bladder, the mean bladder pressure and the number of microcontractions decreased after mirabegron administration, whereas these parameters did not change with oxybutynin administration. SAAs of Aδ-fibers were significantly decreased by mirabegron administration at both 0.3 and 1mg/kg, whereas SAAs of C-fibers decreased only at 1mg/kg. In contrast, oxybutynin (1mg/kg) did not alter either type of SAA.
CONCLUSIONS: The present study demonstrates that mirabegron can inhibit mechanosensitive bladder afferent activity, especially of Aδ-fibers, which may be related to suppression of bladder microcontractions.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22981677     DOI: 10.1016/j.eururo.2012.08.056

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  30 in total

Review 1.  β3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions?

Authors:  Yasuhiko Igawa; Naoki Aizawa; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-05-03       Impact factor: 8.739

2.  Incontinence: How do β3-adrenoceptor agonists work in the bladder?

Authors:  Yasuhiko Igawa; Naoki Aizawa
Journal:  Nat Rev Urol       Date:  2017-03-21       Impact factor: 14.432

3.  A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle.

Authors:  Prajni Sadananda; Marcus J Drake; Julian F R Paton; Anthony E Pickering
Journal:  J Pharmacol Exp Ther       Date:  2013-09-05       Impact factor: 4.030

4.  Effects of nicotinic receptor agonists on bladder afferent nerve activity in an in vitro bladder-pelvic nerve preparation.

Authors:  Yongbei Yu; Stephanie L Daugherty; William C de Groat
Journal:  Brain Res       Date:  2016-02-11       Impact factor: 3.252

5.  Mirabegron as adjuvant treatment for patients with interstitial cystitis/bladder pain syndrome.

Authors:  Michael Di Lena; Victoria Tolls; Kerri-Lynn Kelly; J Curtis Nickel
Journal:  Can Urol Assoc J       Date:  2017-12-22       Impact factor: 1.862

6.  Mirabegron, a Clinically Approved β3 Adrenergic Receptor Agonist, Does Not Reduce Infarct Size in a Swine Model of Reperfused Myocardial Infarction.

Authors:  Xavier Rossello; Antonio Piñero; Rodrigo Fernández-Jiménez; Javier Sánchez-González; Gonzalo Pizarro; Carlos Galán-Arriola; Manuel Lobo-Gonzalez; Jean Paul Vilchez; Jaime García-Prieto; Jose Manuel García-Ruiz; Ana García-Álvarez; David Sanz-Rosa; Borja Ibanez
Journal:  J Cardiovasc Transl Res       Date:  2018-08-02       Impact factor: 4.132

7.  Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats.

Authors:  Toshiki Hatanaka; Masashi Ukai; Mai Watanabe; Akiyoshi Someya; Akiyoshi Ohtake; Masanori Suzuki; Koji Ueshima; Shuichi Sato; Seiji Kaku
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

8.  Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms?

Authors:  Maya Basu; Aswini Balachandran; Jonathan Duckett
Journal:  Int Urogynecol J       Date:  2015-08-19       Impact factor: 2.894

Review 9.  β3-receptor agonists for overactive bladder--new frontier or more of the same?

Authors:  Karl-Erik Andersson
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 10.  Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.

Authors:  Ilias Giarenis; Dudley Robinson; Linda Cardozo
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.